All In MedTech

Device Trial Radar · NCT05874635

Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)

Use of Signos mHealth Platform in Participants With Non-Insulin Dependent Type 2 Diabetes: Weight and Blood Glucose

Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20,000

Planned (sponsor's estimate)

Start

May 11, 2023

Primary completion

May 10, 2028

Study completion May 10, 2029

Sponsor

Lead sponsor
Signos IncNot on our public-company list
Sponsor type
Industry
First posted
May 25, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The use of continuous glucose monitoring (CGM) in earlier data has inspired behavioral changes leading to improved adherence to an exercise plan in individuals and eating habits in people with diabetes. Mobile health (mHealth) platforms provide satisfactory, easy-to-use tools to help participants in the pursuit of weight change goals. We hypothesize that the use of CGM data and the Signos mHealth platform will assist with weight control in a population of people with type 2 diabetes mellitus who are not using insulin.

Conditions

  • Weight Loss
  • Metabolic Syndrome
  • Diabetes Mellitus, Type 2
  • Central Obesity
  • Insulin Resistance
  • Glucose Intolerance
  • Metabolic Glucose Disorders

Interventions

  • Continuous Glucose Monitor DeviceDevice

    Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glucose Metrics via Continuous Glucose Measurement (CGM)Time frame: During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.
  2. Change in weight in poundsTime frame: During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.
  3. App engagementTime frame: During enrollment in the trial for a maximum of 5 years, including a 1 year follow up period, for a maximum of 6 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Signos

    Palo Alto, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.